Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
OKYO Pharma insiders acquire shares
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company's shares at US$1.04 per share. Additionally, Panetta Partners, in which executive chairman Gabriele Cerrone holds a beneficial interest, purchased 20,000 shares at the same price.
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end
OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for the six months ending in September 2024. The company said it expects to complete enrollment of its Phase 2a trial of its investigational therapeutic OK-101 in neuropathic corneal pain (NCP) by the end of the second quarter.
OKYO Pharma secures non-dilutive funding to advance clinical programs
OKYO Pharma Ltd (NASDAQ:OKYO) has announced the receipt of $1.4 million in non-dilutive funding. The clinical-stage biopharmaceutical company is developing novel therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED), This funding will support the company's ongoing research and development efforts, with a primary focus on advancing its lead program, OK-101, designed to treat NCP, a condition with no FDA-approved therapies.
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference
OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference in Venice, Italy, being held from October 30 to November 2, 2024. Dr Raj Patil, OKYO's chief scientific officer, will present efficacy and safety data from the Phase 2 trial of OK-101, OKYO's leading candidate for treating dry eye disease (DED), on November 2.
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company's Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic corneal pain (NCP). Jacob highlighted a significant milestone for the trial: the first patient dosed.
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational therapeutic topical OK-101 to treat neuropathic corneal pain (NCP). NCP, which is believed to be caused by nerve damage to the cornea combined with inflammation, causes pain and sensitivity of the eyes, face or head.
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at treating neuropathic corneal pain (NCP). The trial comes as part of OKYO's broader efforts to address unmet needs in the billion-dollar inflammatory dry eye disease (DED) market and NCP, an eye condition characterized by severe eye pain and sensitivity with no approved therapies.
OKYO Pharma secures key US patent for dry eye disease therapy
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101's use to treat irritated, burning eyes and blurred vision in patients with dry eye disease (DED) The patent, issued on August 6, is US patent no. 12,053,503 titled “Methods for Treating Symptoms of Dry Eye Disease.
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd. (Nasdaq:OKYO) and SolarMax Technology, Inc. (Nasdaq:SMXT) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 24, at 7 p.m.
OKYO Pharma chairman acquires more shares in the company
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman Gabriele Cerrone has a beneficial interest, has purchased 35,000 shares of the company at $1 each. The company said the purchase brings Cerrone's total shareholding to 9,671,570 shares, or 28.58% of issued share capital.
OKYO Pharma lands European patent protection for lead asset
OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs and Methods of Use, it covers OK-101 chemerin analogs, strengthening the drug developer's intellectual property in ocular inflammatory and pain conditions.
OKYO Pharma dry eye disease trial to get underway in the third quarter
OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in the third quarter. In earlier studies, OK-101 showed significant pain relief for dry eye disease patients and reduced NCP in animal models.
